Get the Stockscreener App
32.66
5.76%
-2.12
Tg Therapeutics Inc stock is traded at $32.66, with a volume of 1.86M.
It is down -5.76% in the last 24 hours and down -10.71% over the past month.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
See More
Previous Close:
$34.78
Open:
$36.3
24h Volume:
1.86M
Relative Volume:
0.85
Market Cap:
$5.21B
Revenue:
$264.79M
Net Income/Loss:
$-14.36M
P/E Ratio:
-296.91
EPS:
-0.11
Net Cash Flow:
$-28.11M
1W Performance:
-2.72%
1M Performance:
-10.71%
6M Performance:
-24.55%
1Y Performance:
+21.84%
1-Day Range:
$31.07
$36.50
1-Week Range:
$31.07
$36.65
52-Week Range:
$22.92
$46.48
Tg Therapeutics Inc Stock (TGTX) Company Profile
Name
Tg Therapeutics Inc
Sector
Industry
Phone
(212) 554-4484
Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
32.87 | 5.52B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.38 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
636.02 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.39 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.56 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.97 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-25 | Resumed | H.C. Wainwright | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Oct-29-24 | Initiated | TD Cowen | Buy |
| Aug-02-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-26-23 | Resumed | Jefferies | Buy |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-19-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-01-20 | Initiated | JP Morgan | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Initiated | Evercore ISI | Outperform |
| Jan-17-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Sep-25-18 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-01-17 | Resumed | B. Riley FBR, Inc. | Buy |
| Nov-14-17 | Resumed | H.C. Wainwright | Buy |
| Apr-25-17 | Initiated | Jefferies | Buy |
| Mar-06-17 | Reiterated | FBR & Co. | Outperform |
| Oct-06-16 | Resumed | Brean Capital | Buy |
| May-27-16 | Initiated | SunTrust | Buy |
| Dec-01-15 | Initiated | FBR Capital | Outperform |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| Aug-12-15 | Resumed | H.C. Wainwright | Buy |
| Jun-19-15 | Reiterated | Brean Capital | Buy |
| Dec-11-14 | Reiterated | ROTH Capital | Buy |
| Dec-10-14 | Reiterated | ROTH Capital | Buy |
View All
Tg Therapeutics Inc Stock (TGTX) Latest News
Earnings call transcript: TG Therapeutics Q3 2025 beats EPS forecast, stock dips - Investing.com
TG Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug - Stocktwits
TG Therapeutics (TGTX) Reports Strong Q3, Raises 2025 Revenue Gu - GuruFocus
TG Therapeutics Inc (TGTX) Reports Q3 2025 Revenue of $161.7 Mil - GuruFocus
TG Therapeutics (TGTX) Increases 2025 BRIUMVI Revenue Forecast - GuruFocus
TG Therapeutics: Q3 Earnings Snapshot - News-Times
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance - TradingView
TG Therapeutics (TGTX) Surpasses Q3 Revenue Expectations and Exp - GuruFocus
Earnings Flash (TGTX) TG Therapeutics, Inc. Reports Q3 Revenue $161.7M, vs. FactSet Est of $152.1M - MarketScreener
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update - MarketScreener
How TG Therapeutics Inc. stock compares to industry benchmarksWeekly Market Summary & Free Safe Entry Trade Signal Reports - newser.com
TG Therapeutics Builds On BRIUMVI's Momentum Ahead Of Q3 Earnings And 2027 Launch Plans - RTTNews
Analyzing recovery setups for TG Therapeutics Inc. investorsBuy Signal & Verified Swing Trading Watchlists - newser.com
Is it time to cut losses on TG Therapeutics Inc.Dividend Hike & Daily Chart Pattern Signal Reports - newser.com
Is TG Therapeutics Inc. stock oversold or undervaluedJuly 2025 Earnings & Precise Buy Zone Identification - newser.com
How TG Therapeutics Inc. (NKB2) stock trades under stagflationQuarterly Growth Report & Verified Trade Idea Suggestions - newser.com
What dividend safety score for TG Therapeutics Inc. stock2025 Retail Activity & Low Risk Entry Point Tips - newser.com
How to escape a deep drawdown in TG Therapeutics Inc.Breakout Watch & Daily Chart Pattern Signal Reports - newser.com
Is TG Therapeutics Inc. stock a good choice for value investorsJuly 2025 Spike Watch & High Return Trade Opportunity Guides - newser.com
Will TG Therapeutics Inc. stock outperform value stocksJuly 2025 Reactions & Short-Term High Return Strategies - newser.com
TG Therapeutics Inc Stock Analysis and ForecastMonthly Performance Summary & Small Investment Portfolio Growth - earlytimes.in
Tools to assess TG Therapeutics Inc.’s risk profileJuly 2025 Institutional & Scalable Portfolio Growth Methods - newser.com
How to build a dashboard for TG Therapeutics Inc. stock2025 Performance Recap & AI Driven Stock Reports - newser.com
Is TG Therapeutics Inc. stock gaining market shareWeekly Trade Report & Community Shared Stock Ideas - newser.com
Building trade automation scripts for TG Therapeutics Inc.Market Trend Summary & AI Forecast Swing Trade Picks - newser.com
Is now a turning point for TG Therapeutics Inc.Weekly Earnings Recap & Expert Approved Trade Ideas - newser.com
TG Therapeutics, Inc. $TGTX Stock Position Reduced by State of New Jersey Common Pension Fund D - MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
TG Therapeutics to Host Conference Call for Third Quarter 2025 Results on November 3, 2025 - Quiver Quantitative
TG Therapeutics (NASDAQ: TGTX) schedules Q3 results call, 8:30 a.m. ET, business update - Stock Titan
Will TG Therapeutics Inc. stock attract ESG investors2025 Key Highlights & Detailed Earnings Play Strategies - newser.com
What Wall Street predicts for TG Therapeutics Inc. stock priceEarnings Trend Report & Precise Swing Trade Entry Alerts - newser.com
A Fresh Look at TG Therapeutics (TGTX) Valuation Following Phase 3 ENHANCE Trial Enrollment Completion - Sahm
Yorktown Management & Research Co Inc Invests $383,000 in TG Therapeutics, Inc. $TGTX - MarketBeat
TG Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Tg Therapeutics Inc Stock (TGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):